Dengue is a severe mosquito-borne viral infection causing half a million deaths annually. Dengue virus NS2B/NS3 protease is a validated target for anti-dengue drug design. A series of hitherto unreported 3,5-bis(arylidene)-4-piperidones analogues - were synthesized and screened against DENV2 NS2B/NS3 protease to elucidate their binding mechanism and orientation around the active sites. Results were validated through an DENV2 NS2B/NS3 protease assay using a fluorogenic Boc-Gly-Arg-Arg-AMC substrate. Nitro derivatives of 3,5-bis(arylidene)-4-piperidones ( and ) emerged as promising lead molecules for novel protease inhibitors with an IC of 15.22 and 16.23 µmol/L, respectively, compared to the standard, panduratin A, having IC of 57.28 µmol/L.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518655PMC
http://dx.doi.org/10.1016/j.apsb.2017.04.009DOI Listing

Publication Analysis

Top Keywords

ns2b/ns3 protease
12
protease inhibitors
8
denv2 ns2b/ns3
8
protease
5
35-bisarylidene-4-piperidones potential
4
potential dengue
4
dengue protease
4
inhibitors dengue
4
dengue severe
4
severe mosquito-borne
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!